Article citationsMore>>
Lin, N.U., Carey, L.A., Liu, M.C., Younger, J., Come, S.E., Ewend, M., Harris, G., Bullitt, E., Van den Abbeele, A.D., Henson, J.W., Li, X., Gelman, R., Burstein, H.J., Kasparian, E., Kirsch, D.G., Crawford, A., Hochberg, F. and Winer, E.P. (2008) Phase II Trial of Lapatinib for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 26, 1993-1999.
http://dx.doi.org/10.1200/JCO.2007.12.3588
has been cited by the following article:
-
TITLE:
Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine
AUTHORS:
C. P. Coyne, Toni Jones, Ryan Bear
KEYWORDS:
Gemcitabine, Anti-EGFR, Anti-HER2/neu, Covalent Immunochemotherapeutic, Gemcitabine-(C4-amide)-[Anti-EGFR], Gemcitabine-(C4-amide)-[Anti-HER2/neu], Mammary Adenocarcinoma (SKBr-3), [Se]-Methylselenocysteine
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.1,
January
16,
2015
ABSTRACT:
The anti-metabolite chemotherapeutic, gemcitabine is relatively
effective for a spectrum of neoplastic conditions that include various forms of
leukemia and adenocarcinoma/carcinoma. Rapid systemic deamination of
gemcitabine accounts for a brief plasma half-life but its sustained
administration is often curtailed by sequelae and chemotherapeutic-resistance.
A molecular strategy that diminishes these limitations is the molecular design
and synthetic production of covalent gemcitabine immunoche-motherapeutics that possess properties of selective
“targeted” delivery. The simultaneous dual selective “targeted” delivery of
gemcitabine at two separate sites on the external surface membrane of a single
cancer cell types represents a therapeutic approach that can increase cytosol
chemotherapeutic deposition; prolong chemotherapeutic plasma half-life (reduces
administration frequency); minimize innocent exposure of normal tissues and
healthy organ systems; and ultimately enhance more rapid and thorough
resolution of neoplastic cell populations. Materials and Methods: A
light-reactive gemcitabine intermediate synthesized utilizing succinimidyl
4,4-azipentanoate was covalently bound to anti-EGFR or anti-HER2/neu IgG
by exposure to UV light (354-nm) resulting in the synthesis of covalent
immunoche-motherapeutics, gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu]. Cytotoxic anti-neoplastic potency of gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu] betweengemcitabine-equivalent
concentrations of 10-12 M
and 10-6 M
was determined utilizing chemotherapeutic-resistant mammary adenocarcinoma
(SKRr-3). The organoselenium compound, [Se]-methylselenocysteine was evaluated
to determine if it complemented the anti-neoplastic potency of the covalent
gemcitabine immunoche-motherapeutics.
Results: Gemcitabine-(C4-amide)-[anti-EGFR],
gemcitabine-(C4-amide)-[anti-HER2/neu] and the dual simultaneous combination of gemcitabine-(C4-amide)-[anti-EGFR] with gemcitabine-(C4-amide)-[anti-HER2/neu] all had anti-neoplastic cytotoxic potency against mammary
adenocarcinoma. Gemcitabine-(C4-amide)-[anti-EGFR]
and gemcitabine-(C4-amide)-[anti-HER2/neu] produced progressive increases in anti-neoplastic
cytotoxicity that were greatest between gemcitabine-equivalent concentrations
of 10-9 M and 10-6 M.
Dual simultaneous combinations of gemcitabine-(C4-amide)-[anti-EGFR]
with gemcitabine-(C4-amide)-[anti-HER2/neu] produced levels of anti-neoplastic cytotoxicity
intermediate between each of the individual covalent gemcitabine
immunochemotherapeutics. Total anti-neoplastic cytotoxicity of the dual
simultaneous combination of gemcitabine-(C4-amide)-[anti-EGFR]
and gemcitabine-(C4-amide)-[anti-HER2/neu] against chemothe-rapeutic-resistant
mammary adenocarcinoma (SKBr-3) was substantially higher when formulated with
[Se]-methylsele-no-cysteine.
Related Articles:
-
Anja Brügmann, V. Jensen, J. P. Garne, E. Nexo, B. S. Sorensen
-
Soheir S. Ismail, Soheir H. Mahmoud, Dina A. Salem, Ahmed E. Essa, Diaa El-Din M. Sherif
-
May El Sherif, Claus Peter Schneider, Carola Rabenstein, Amina Hessein Hassab, Magdy Mamdouh El Bordiny, Mona Wagdy Ayad, Katharina Pachmann
-
Kengo Hirayama, Ya Su, Yasuyuki Ikezawa, Megumi Chiba, Kenichiro Ito, Michiko Yuki
-
Jai Dev Chandel, Nand Lal Singh